A comparison of healthy heart with contracted muscle (left) and a weakened heart with over-stretched muscle (right). Credit: Manu5.

Boehringer Ingelheim and Eli Lilly are set to expand their existing clinical trial programme for empagliflozin in chronic heart failure with new exercise capacity trials.

The EMPERIAL trials are designed to examine the effect of empagliflozin on exercise ability and heart failure symptoms in people with chronic heart failure, regardless of whether they have type 2 diabetes. The studies are scheduled to be completed next year.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The trials feature two Phase III randomised, double-blind studies, EMPERIAL-preserved (NCT03448406) and EMPERIAL-reduced (NCT03448419).

Both trials are set to assess the effect of 12 weeks’ treatment with empagliflozin on the ability of people with heart failure to perform daily exercise.

EMPERIAL-preserved is expected to examine empagliflozin in patients with chronic heart failure with preserved ejection fraction (HFpEF).

“Currently, there are limited treatment options that can help improve the everyday lives of people living with chronic heart failure.”

The trial’s primary endpoint includes change from baseline to week 12 in exercise capacity as measured by the distance walked in six minutes. It aims to enrol around 300 patients, with plans to do the same next year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

EMPERIAL-reduced will examine empagliflozin in patients with chronic heart failure with reduced ejection fraction (HFrEF).

The primary endpoint of the trial is the change from baseline to week 12 in exercise capacity as measured by the distance walked in six minutes.

Lilly Diabetes Product Development vice-president Jeff Emmick said: “Symptoms of heart failure can have a profound effect on quality of life, with more than three quarters of people with heart failure finding it difficult to carry out routine activities.

“Currently, there are limited treatment options that can help improve the everyday lives of people living with chronic heart failure.”

Heart failure, a serious condition where the heart is unable to pump enough blood around the body, is estimated to affect 26 million people worldwide. Roughly 50% of those who develop heart failure die within five years.